US2002115687A1PendingUtilityA1

Method and composition for restoring diuretic and renal function

48
Priority: Apr 24, 1998Filed: May 21, 2001Published: Aug 22, 2002
Est. expiryApr 24, 2018(expired)· nominal 20-yr term from priority
Inventors:Evan BeckmanGlenn Smits
A61K 31/56A61K 31/635A61K 31/52A61K 31/64A61K 31/549A61K 31/58A61K 31/54
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for restoring diuretic and renal function.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A composition comprising a pharmaceutically effective amount of an adenosine A1 antagonist and a non-adenosine modifying diuretic.  
     
     
         2 . The composition of  claim 1  wherein the adenosine A1 antagonist is BG9719.  
     
     
         3 . The composition of  claim 1  wherein the diuretic is selected from the group consisting of hydrochlorothiazides, furosemide, torsumide, bumetanide, thacrynic acid, piretanide, norsemide, spironolactone, triamterene, and amiloridethiazides.  
     
     
         4 . A method of inducing a diuretic effect in a animal refractory to a diuretic comprising the step of administering a therapeutically effective amount of an adenosine A1 antagonist in combination with second pharmaceutical composition capable of inducing a diuretic effect.  
     
     
         5 . The method of  claim 4  wherein the adenosine A1 antagonist is BG9719, salts, esters or analogs thereof.  
     
     
         6 . The method of  claim 4  wherein the diuretic is selected from the group consisting of hydrochlorothiazides, furosemide, torsumide, bumetanide, thacrynic acid, piretanide, norsemide, spironolactone, triamterene, and amiloridethiazides.  
     
     
         7 . The method of  claim 4  wherein the diuretic is administered subsequent to the administration of the adenosine A1 antagonist.  
     
     
         8 . The method of  claim 4  wherein the diuretic is administered substantially simultaneously with the adenosine A1 antagonist.  
     
     
         9 . The method of  claim 4  wherein the diuretic is administered prior to the adenosine A1 antagonist.  
     
     
         10 . A method of maintaining or restoring the diuretic effect of a non-adenosine modifying diuretic in a patient comprising the administration of an adenosine A1 antagonist in combination with said non-adenosine modifying diuretic.  
     
     
         11 . The method of  claim 10  wherein the diuretic is furosemide.  
     
     
         12 . The method of  claim 10  wherein the adenosine A1 antagonist is BG9719, salts, esters, or analogs thereof.  
     
     
         13 . A method of maintaining or restoring renal function in a patient comprising the step of administering a therapeutically effective amount of an adenosine A1 antagonist in combination with second pharmaceutical composition capable of inducing a diuretic effect.  
     
     
         14 . The method of  claim 13  wherein said second pharmaceutical composition comprises a loop diuretic and a distal diuretic.  
     
     
         15 . A method of maintaining or restoring renal function in a patient comprising the steps of: 
 a) administering to said patient a therapeutically effective amount of a non-adenosine modifying diuretic;    b) monitoring the glomerular filtration rate of said patient;    c) if the rate measure in step b) falls 20% or more below a normal glomerular filtration rate, administering to said patient a therapeutically effective amount of an adenosine A1 antagonist.    
     
     
         16 . The method of  claim 15  wherein the agonist is BG9719.  
     
     
         17 . A method of treating a patient refractory to diuresis with a pharmaceutical composition of  claim 1.

Join the waitlist — get patent alerts

Track US2002115687A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.